Submission of audited financial results for the quarter and financial year ended 3st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 3.3 pts less than its Diversified Commercial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Johnson Pharmacare Ltd reported a massive net loss of ₹5,573.39 Lacs for FY2026, compared to a loss of ₹58.38 Lacs in the previous year. Total income was ₹158.10 Lacs while total expenses stood at ₹4,304.49 Lacs. The company incurred exceptional items of ₹1,427.00 Lacs and reported negative other equity of ₹5,456.48 Lacs. Cash losses amounted to ₹11,123.52 Lacs. The auditors from VRSK & Associates issued a qualified opinion citing non-compliance with Ind AS, non-provision of interest on loans, and qualified opinion on internal financial controls. The company has borrowings of ₹2,140.19 Lacs and pending tax demands including ₹233.02 Lacs from AY 1996-97. There was also a change in auditors during the year.
The company is in severe financial distress with massive losses, negative equity, and auditor concerns about ability to meet short-term liabilities. Shareholders should be extremely cautious as the company faces going concern risks despite auditor's nominal statement otherwise.